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ABSTRACT 
Objective: The objective of the present work was to improve aqueous solubility and in vivo bioavailability of curcumin and structural analogues of 
curcumin such as potassium, calcium, magnesium salts and nitro derivative.  
Methods: Structural analogues of curcumin were prepared by reaction of curcumin with potassium chloride, magnesium chloride hexahydrate and 
calcium chloride dihydrate in a suitable solvent. The nitro derivative synthesized by treating curcumin with sulphuric acid and nitric acid. The 
prepared analogues were evaluated for melting behavior, solubility, UV spectrophotometry, partition coefficient, moisture content, cellular uptake, 
FTIR analysis, antimicrobial activity and in vivo bioavailability in the rat.  
Results: Chemical modification of curcumin increased the saturation solubility to 11.6, 16.5, 21.5, 28.0 µg/ml in calcium salt, magnesium salt, 
potassium salt and nitro derivative respectively, against 8.6 µg/ml of curcumin. The analogues were chemically stable as curcumin analyzed by FTIR 
spectrophotometry. Increased cellular uptake, as well as enhanced antimicrobial activity, was demonstrated by modified curcumin analogues. 
Moreover, significant improvement in plasma levels was estimated with nitro derivative.  
Conclusion: The present work recommends that nitration of curcumin improves aqueous solubility which may improve absorption and in vivo 
bioavailability. 
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INTRODUCTION 
Curcumin, a naturally occurring polyphenolic diferuloylmethane 
extracted from the rhizomes of plant Curcuma longa Linn. (Family: 
Zingiberaceae) has potential in the prevention and therapeutic 
interventions of several pathological conditions including respiratory 
diseases, inflammation, liver disorders and diabetic wounds. It prevents 
a variety of carcinogen-induced cancers in rodents by suppressing the 
mutagenic effects of carcinogens [1]. In addition, the hepato-and nephro-
protective, thrombosis suppressing, myocardial infarction protective, 
hypoglycemic, and antirheumatic effects of curcumin are also reported 
[2-4]. Several animal and human studies have demonstrated the safety 
for curcumin at very high doses (12 g/d) [5-7] which makes it a potential 
compound for treatment and prevention of a wide variety of human 
diseases. In spite of its efficacy and safety, curcumin has not yet been 
approved as a therapeutic agent due to its low bioavailability presenting 
a significant pharmacological obstacle for clinical application. It is a 
hydrophobic compound with poor aqueous solubility and low 
absorption. It undergoes rapid metabolism and rapid systemic 
elimination further diminishing the bioavailability. The solubility of 
curcumin in water especially at acidic and physiological pH is extremely 
low (11 ng/ml). It undergoes rapidly hydrolysis under alkaline 
conditions and readily decomposed when exposed to bright light, high 
temperature or oxidative conditions [8]. Based on its poor aqueous 
solubility and permeability, curcumin can be classified as a BCS class IV 
molecule [9]. Effective pharmacokinetics is a surrogate for 
pharmacodynamics and is a determinant of therapeutic outcome. 
Although curcumin showed potential pharmacodynamics, it has poor 
pharmacokinetic characteristics. Many attempts have been made to 
increase solubility, absorption (permeability) and stability of curcumin 
in order to increase bioavailability.  
Although many clinical trials for curcumin are currently ongoing 
[10], its clinical advancement of is hampered by its poor water 
solubility and short biological half-life and low bioavailability in 
both plasma and tissues [11-13]. The oral bioavailability of 
curcumin and synthetic structural analogues of curcumin is very low 
(only 1% in rats)
The motivation for building curcumin analogues is based upon its 
rapid metabolism and conjugation in the liver and its excretion 
through feces which limit the systemic bioavailability. In order to 
overcome these limitations, several approaches have been 
attempted including the combination of curcumin with adjuvants 
such as piperine
 [14-16]. 
MATERIALS AND METHODS 
 [17] and the development of delivery vehicles 
consisting of liposomes nanoparticles a phospholipid complex [18-
20]. Several efforts for improving the systemic and tissue 
bioavailability of curcumin have largely been unsuccessful. The aim 
of the present work is to improve aqueous solubility and in vivo 
bioavailability of curcumin by using its structural analogues. 
Curcumin was received as gift sample from the Baidhyanath Pvt. 
Limited (Nagpur, India). Potassium hydroxide, calcium chloride 
dehydrate, magnesium chloride hexahydrate, and nitric acid, 
sulphuric acid were obtained from Merck Specialities Private 
Limited, Fisher Scientific and HiMedia Laboratories (Mumbai, India).  
Preparation of structural analogues of curcumin 
The structural analogues of curcumin were prepared by reaction of 
curcumin with potassium chloride, magnesium chloride hexahydrate 
and calcium chloride dihydrate in a suitable solvent (methanol, 
water). Salts were recrystallized and the resulting crystals were 
washed and dried [21]. The nitro derivative of curcumin 
synthesized, washed and dried [22].  
Preparation of potassium salt 
Aqueous 80 ml KOH was added to a solution of 5 g curcumin in 40 ml 
chloroform. The mixture was sonicated for 4 h. The organic layer was 
evaporated and aqueous layer was washed with a respective solvent. 
Salt was recrystallized with ethanol-water mixture and dried [23]. 
Preparation of calcium salt 
A solution of calcium chloride dihydrate in 50 ml of water was added 
to a solution of 20 g potassium salt in 250 ml warm water. Stirring 
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was continued for 3 h, and then the crystals were filtered and 
washed with water. By using Potassium salt, calcium salts was 
prepared [23]. 
Preparation of magnesium salt 
A solution of magnesium chloride hexahydrate in a 100 ml of water 
was added with stirring to a solution of 20 g potassium salt in 250 
ml warm water. Stirring was continued for 3 h, and then the crystals 
were filtered and washed with water [23]. 
Preparation of nitro derivative 
Curcumin was reacted with the mixture of sulphuric acid and nitric 
acid for 6 h in the reaction vessel. Then the mixture was filtered, 
washed and dried [23]. 
Evaluation of structural analogues of curcumin 
Melting point determination 
Melting point of curcumin and its structural analogues were 
determined in an electric melting point apparatus (Elico, India) by 
capillary method.  
UV spectrophotometric analysis 
Analysis of curcumin and its structural analogue in methanol was 
carried out using UV Spectrophotometer (Jasco, U. S. A.). 
Solubility study using the shake-flask method 
Saturated solutions of curcumin and its structural analogues were 
prepared by mixing an excess of solid solute in 10 ml distilled water. 
Then these mixtures were agitated in mechanical shaker 
thermostated at 30 °C±0.1 ° C for 24 h. The filtered samples were 
diluted and analyzed by UV Spectrophotometry [24]. 
Moisture content determination 
Approximately 1g of the sample was dehydrated in hot air oven at 
60 °C and reweighed at an interval of 10 min till the constant weight 
for three consecutive determinations and % moisture loss was 
calculated.  
Partition coefficient determination 
The partition coefficient was determined using the shake-flask 
method. An excess amount of curcumin was shaken in an equal 
volume of octanol and water in a separating funnel. Then it was kept 
aside to separate the layers octanol and water. The separated layers 
were analyzed using uv-spectrophotometer at 271 nm wavelength.  
Cellular uptake determination 
The cellular uptake of curcumin and its salts/derivative were 
examined by UV spectrophotometry. A constant concentration (100 
µl) of curcumin and its salts were made and mix with an equal 
amount of stock solution of RBC (10 ml in 100 ml). The mixture was 
centrifuged at a fixed rpm at a 37 °C for a 10 min. Supernatant was 
collected and observed against the blank and saline solution [24] 
FTIR analysis 
Curcumin was dried in a hot air oven at 50 °C for 1 h. The samples 
were prepared by mixing it thoroughly with potassium bromide. 
This physical mixture was compressed under of 10 ton/nm2 and 
converted in a circular disc. This disc was then placed in a scanning 
slot of Fourier Transform Infra-red (FTIR) spectrophotometer 
(Shimadzu 1800) and scanned at range from 400 to 4000 cm-1
Antimicrobial assay 
. The 
spectrum was then compared with the spectrum of the reference 
standard. 
Staphylococcus aureus and Escherichia coli (HiMedia Laboratories 
Mumbai, India). were used as the test organisms. Antimicrobial 
efficiency was determined by the Cup-Plate method. Sterile solutions 
of curcumin and its analogues were diluted at different 
concentration these solutions were poured into cups bored into 
sterile nutrient agar previously seeded with the test organisms, after 
allowing diffusion of the solution for 2 h, the agar plates were 
incubated at 37 °C for 24 h. The zone of inhibition (ZOI) measured 
around each cup and was compared with that of control.  
In vivo bioavailability assessment 
Male Sprague rats weighing 250±20 g were randomly divided into 5 
groups and fasted for 10-12 h prior to experiments, although they 
were allowed free access to water. All the experimental protocol was 
carried out according to the guidelines of CPCSEA 
(853/AC/04/CPCSE). A feeding tube was inserted into the mouth of 
rat. The animals in the first groups were orally administered 1 ml of 
0.5 carboxymethyl cellulose (CMC) saline, an aqueous suspension 
containing curcumin at a dose of 100 mg/kg, and those were 
remaining in the other groups were received potassium salt, calcium, 
magnesium, and nitro derivative respectively. Then 50 µl of blood was 
collected from tail vein at a pre-determined interval for a 8h and 
centrifuged at 12000 rpm for 10 min. 
Plasma was mixed with ethyl acetate and extracted twice with it by 
vigorous shaking on a mechanical shaker for 10 min. The upper 
organic layer was removed and placed in a cleaned centrifuge tube. 
The combined organic phase was then evaporated at room 
temperature and the residue was reconstituted with 100 µl mobile 
phase. The 50 µl of supernatant was analyzed by HPLC (Analytical). 
In HPLC mobile phase, THF (40 %) and water containing 1.2 % citric 
acid were used. The flow rate of 1 ml/min was used [24]. 
RESULTS AND DISCUSSION 
Melting points for curcumin and its potassium, magnesium, calcium 
salts and nitro derivative were found to be in the range of 182-184 °C, 
320-325 °C, 310-312 °C, 330-332 °C and 210-220 °C respectively. 
Increased melting point of the salts might be a result of ionic nature of 
the salts. In addition, increased molecular weights of nitro derivative 
also resulted in increased melting temperature and hence require 
more energy for breaking of ionic bonds or ion-dipole or Vander wall 
interaction. The distinguishing and higher melting points confirmed 
the successful synthesis of curcumin derivative and salt. 
 
 
Fig. 1: Overlain of UV spectrum of curcumin and its potassium, calcium, magnesium salts and nitro derivative 
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The UV spectrum was scanned for Curcumin at λmax
The %moisture content for curcumin and its potassium, calcium, 
magnesium salts and nitro derivative were found to be 0.10, 0.22, 
0.44, 0.51 and 0.14 %. The hygroscopic nature of curcumin 
analogues observed as increased compared with curcumin and 
maximum increment was found in magnesium salt of curcumin. 
 271 nm. As 
shown in fig. 1, UV spectra of curcumin and its analogues (salt and 
derivatives) exactly overlap to each other suggesting the intactness 
of the basic moiety of curcumin structure in its analogues. Moreover, 
the spectrum pattern in nitro derivative and calcium salt of 
curcumin showed sharp peak than other analogues. This was due to 
the group present in the nitro derivative of curcumin which shows 
the electronic transitions and responsible for giving sharp peak.  
The solubility for curcumin and its calcium, magnesium, potassium salts, 
and nitro derivative were found to be 8.690±0.068, 11.655±0.22, 
16.502±0.363, and 21.551±0.162, 28.050±0.202 µg/ml in water 
respectively. The solubility of calcium, magnesium, potassium salts and 
nitro derivative of curcumin observed increases in comparison with the 
curcumin. The enhanced solubility can be correlated with salt formation. 
Thus salt particles can get easily ionized, dispersed and immediately 
dissolved in presence of water. The maximum solubility was observed in 
nitro derivative compared with curcumin and its salts. 
The partition coefficient (octanol/water) of curcumin, potassium 
salt, calcium salt, magnesium salt, and nitro derivative of curcumin 
were found to be 0.92085±0.121, 0.46924±0.132, 0.628095±0.121, 
0.84343±0.201 and 0.29229±0.111, respectively. From the above 
observations, with the decreasing partition coefficient the being 
lowest with nitro derivative. The partitioning of salt and derivative 
of curcumin were founds towards the higher level in the water 
phase because of its greater water solubility. Hence, the coefficients 
of salts and derivatives observed at lower range than that of 
curcumin. As higher water solubility required for the absorption of 
the drug through the gastrointestinal tract was shown by prepared 
curcumin analogues compared with curcumin. 
The cellular uptake of curcumin, and its potassium, calcium, 
magnesium salts, and nitro derivative were found to be 86.86±0.755, 
99.05±0.055, 98.13±0.107, 97.32±0.154 and 92.56±0.427 % 
respectively. The highest cellular uptake was observed in potassium 
salt, 99.05±0.055 % of curcumin was found to be taken up by RBCs 
from the solution [24]. 
 
 
Fig. 2: FTIR spectrum of curcumin and its potassium, calcium, magnesium salts and nitro derivative 
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Curcumin Potassium salt of 
curcumin 
Calcium salt of 
curcumin 
Magnesium salt of 
curcumin 
Nitro derivative of 
curcumin 
O-H stretching 3508 3329 3377 3502 3502 
C=O, C=C 1626 1577 1629 1626 1628 
Aromatic C=O 1601 1508 1591 1600 1600 
Phenol, C-O 1429 1454 1415 1427 1427 
Enol 1272 1278 - 1273 1271 
NO - - - - 1548 
 
As shown in fig. 2 and table 1, the band at 3508 cm-1 indicates the 
presence of the hydroxyl group in the curcumin. The band of 
(phenol) alkanes (C-H) observed at 1350-1512 cm-1. FTIR spectrum 
of curcumin exhibited the absorption peaks 3508, 1626, 1601 and 
1429, 1272 cm−1assigned to −OH, C=O, phenol, enol, and C -O-C 
stretching respectively. The results were found to be concurrent 
with a reference spectrum of curcumin [25]. 
FTIR spectrum of calcium salt showed the absorption peaks 3377, 1626, 
1591 and 1415 cm−1associated with O-H, C=O, aromatic C=O, phenol, 
enol stretching respectively. The O-H group shifting was observed in 
calcium salt from 3508 to 3377 cm−1, C=O group was shifted towards the 
lower wavenumber side from 1629 to 1626 cm−1, C-O shifted from 1429 
to 1415 cm−1
FTIR spectrum of potassium salt of curcumin illustrated the 
absorption bands at 3329, 1577, 1508 and 1454, 1278 cm
, enolic functional group is missing in calcium salt may be 
due to ionic nature and replacement of hydrogen ion by calcium cation. 
Moreover, retention of O-H and C=O groups indicated the presence of 
curcumin in its calcium salt in a stable form. 
−1allocated 
to −OH, C=O, aromatic=O, phenol, enol stretching respectively. The 
O-H group shifting was observed in potassium salt from 3508 to 
3329 cm−1, C=O group was shifted towards the lower wavenumber 
from 1629 to 1577 cm−1, C-O shifted from 1429 to 1454 cm−1, enolic 
group moved towards higher wavenumber from 1272 to 1278 cm−1
FTIR spectrum of the magnesium salt of curcumin showed the 
absorption peaks 3508, 1626, 1600 and 1427, 1273 cm
. 
In these, all the functional groups of curcumin retained by its 
potassium salt suggested its chemical stability. 
−1assigned to 
−OH, C=O, aromatic=O, phenol, enol stretching respectively. The O-H 
group shifting was observed in magnesium salt from 3508 to 3502 
cm−1, C-O altered from 1429 to 1427 cm−1
FTIR spectrum of nitro derivative exhibited the absorption bands 
1628, 1626, and 1427, 1271 cm
. In these, all the functional 
groups of curcumin retained by its magnesium salt suggested its 
chemical stability. 
−1assigned to −OH, C=O, aromatic =O, 
phenol, enol stretching respectively. The C-O shifted from 1429 to 
1427 cm−1, enolic group shifts towards lower side from 1272 to 
1271 in nitro derivative. The functional groups of curcumin retained 
by its nitro derivative suggested its chemical stability. Additionally, 
the peak at 1548 cm−1
  
 observed assisted with N-O, suggested the 
formed derivative of curcumin was observed as chemically stable. 
 
Fig. 3: Antibacterial activity of curcumin and its potassium, calcium, magnesium salts and nitro derivative, *values are expressed as 
mean+SEM 
 
Table 2: Pharmacokinetic parameters calculated from the plasma curcumin profile following single oral administration of curcumin, its 
salts and derivative 
Compounds C max ng/ml T max (min) t½ (min) AUC 0-t ng/mlmin 
Curcumin 148.41 70 147.35 23673.6 
Potassium salt of Curcumin 84.91 60 56.87 52294.6 
Calcium salt of Curcumin 97.73 70 163.74 13822.1 
Magnesium salt of Curcumin 112.20 70 114.925 116805 
Nitro derivative of Curcumin 240.17 60 125.12 35971 
*Values are expressed as mean+SEM and n=12 
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Fig. 4: Plasma concentration time profile of curcumin and its potassium, calcium, magnesium salts and nitro derivative 
 
Curcumin analogues showed greater zones of inhibition than 
curcumin observed in fig. 3. Moreover, the in vitro antibacterial 
efficacy of the curcumin was not affected by the salt and derivative 
formation, suggesting the intactness of the necessary structural 
characteristics required for antibacterial activity [25]. 
As shown in fig. 4 and table 2, the Cmax of curcumin was found to be 
148.41 ng/ml. Cmax was increased from 148.41 ng/ml to 240.17 ng/ml 
in case of the nitro derivative. However, in the case of AUC, it was 
increased from 23673.6 to 35971 ng/mlmin. There was no significant 
difference in the time taken to reach the peak concentration (Tmax) of 
curcumin and their analogues. No significant result was obtained in case 
of potassium, magnesium and calcium salt. One of the main reasons for 
the enhance curcumin oral bioavailability by curcumin analogues is the 
excellent efficiency of curcumin analogues in improving the drug 
solubility and in increasing the dissolution rate [26-28]. 
CONCLUSION 
Curcumin possesses diverse pharmacological activities. Its utility 
limits due to its poor water solubility, poor bioavailability and rapid 
metabolism. In consideration to improve aqueous solubility and in 
vivo bioavailability, structural analogues of curcumin such as 
potassium, calcium, magnesium salts and nitro derivative were 
prepared and evaluated. In comparison with curcumin, its analogues 
exhibited more aqueous solubility. The enhanced solubility data 
were supported by UV spectral analysis, partition coefficient 
determination as well as improved cellular uptake by RBC. The 
analogues were chemically stable as curcumin, which were analyzed 
by FTIR. The curcumin analogues showed greater antibacterial 
activity compared with curcumin. The in vivo bioavailability 
assessment showed that nitro derivative of curcumin illustrated 
greater C max and AUC than curcumin, suggests improved 
bioavailability and limits metabolism. The present work 
recommends that nitration of curcumin improves aqueous solubility 
which may improve absorption and in vivo bioavailability in rat. 
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